Noreva BE SRL
Noreva BE reported total assets of 99,431 € at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jan 2026).
The score of Noreva BE shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1744 % Total assets -29 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Noreva BE's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 16 Jan 2026
- Year ended 30 Sep 2024filed on 02 Dec 2024
- Year ended 30 Sep 2023filed on 15 Jan 2024
- Year ended 30 Sep 2022filed on 03 Jan 2023
- Year ended 30 Sep 2021filed on 09 Mar 2022
Noreva BE's financial analysis
- Solvency75.8%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Noreva BE
Noreva BE's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0647.650.984
- VAT number
- BE0647650984
- Peppol
- Registered · 0208:0647650984 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Jan 2016
- Registered office
- 9051 Ghent
- Latest accounts
- 2025 · filed on 16 Jan 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Noreva BE (SRL) has been based in Ghent since 2016, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 42,842 € and equity of 75,384 €; its revenue is not published. Its solvency stands at 75.8%, above the median of its sector (46.0%).
Companies similar to Noreva BE
Companies in the same business, of comparable size and area, outside its group.
- Zabrus Wholesale of pharmaceutical and medical goods Sint-Martens-Latem · balance sheet 119,641 €
- Reynaert Research Wholesale of pharmaceutical and medical goods Ghent · balance sheet 46,825 €
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- NBS Scientific Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 152,659 €
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
Frequently asked questions about Noreva BE
What is the revenue of Noreva BE?
Noreva BE files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Noreva BE?
In Belgium, the VAT number is the company number prefixed with BE: BE0647650984 for Noreva BE, if the company is VAT-registered. Its company number (CBE) is 0647.650.984.
Where is the registered office of Noreva BE?
According to the CBE register, the registered office of Noreva BE is in 9051 Ghent.
What is the equity of Noreva BE?
At the close of the 2025 financial year, the equity of Noreva BE amounts to 75,384 €, a solvency of 75.8% of total assets.
Who manages Noreva BE?
The register lists 2 active mandates at Noreva BE. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Noreva BE
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →